RS64477B1 - Novi derivati ftalazinona i postupak njihove proizvodnje - Google Patents
Novi derivati ftalazinona i postupak njihove proizvodnjeInfo
- Publication number
- RS64477B1 RS64477B1 RS20230721A RSP20230721A RS64477B1 RS 64477 B1 RS64477 B1 RS 64477B1 RS 20230721 A RS20230721 A RS 20230721A RS P20230721 A RSP20230721 A RS P20230721A RS 64477 B1 RS64477 B1 RS 64477B1
- Authority
- RS
- Serbia
- Prior art keywords
- carbonyl
- phthalazin
- compound
- fluoro
- azetidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130110170 | 2013-09-13 | ||
| KR1020140120152A KR101670126B1 (ko) | 2013-09-13 | 2014-09-11 | 신규 프탈라지논 유도체 및 그 제조방법 |
| PCT/KR2014/008523 WO2015037939A1 (en) | 2013-09-13 | 2014-09-12 | A novel phtalazinone derivatives and manufacturing process thereof |
| EP14843941.7A EP3030557B1 (en) | 2013-09-13 | 2014-09-12 | A novel phtalazinone derivatives and manufacturing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64477B1 true RS64477B1 (sr) | 2023-09-29 |
Family
ID=53024930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20230721A RS64477B1 (sr) | 2013-09-13 | 2014-09-12 | Novi derivati ftalazinona i postupak njihove proizvodnje |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | USRE49338E1 (https=) |
| EP (1) | EP3030557B1 (https=) |
| JP (1) | JP6180643B2 (https=) |
| KR (1) | KR101670126B1 (https=) |
| CN (1) | CN105793248B (https=) |
| AU (1) | AU2014319132C1 (https=) |
| BR (1) | BR112016004979B1 (https=) |
| CA (1) | CA2923614C (https=) |
| DK (1) | DK3030557T3 (https=) |
| ES (1) | ES2953834T3 (https=) |
| FI (1) | FI3030557T3 (https=) |
| HR (1) | HRP20230998T1 (https=) |
| HU (1) | HUE062770T2 (https=) |
| IL (1) | IL244548B (https=) |
| LT (1) | LT3030557T (https=) |
| MX (1) | MX379467B (https=) |
| MY (1) | MY195343A (https=) |
| PL (1) | PL3030557T3 (https=) |
| PT (1) | PT3030557T (https=) |
| RS (1) | RS64477B1 (https=) |
| RU (1) | RU2636585C2 (https=) |
| SG (1) | SG11201600549TA (https=) |
| SI (1) | SI3030557T1 (https=) |
| SM (1) | SMT202300268T1 (https=) |
| WO (1) | WO2015037939A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| JP2021516229A (ja) * | 2018-02-28 | 2021-07-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 低親和性ポリ（ａｄ−リボース）ポリメラーゼ１依存性細胞毒性剤 |
| US11390608B2 (en) * | 2020-04-21 | 2022-07-19 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
| US12060345B2 (en) | 2020-04-21 | 2024-08-13 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| WO2021225407A1 (ko) * | 2020-05-08 | 2021-11-11 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US20230391752A1 (en) * | 2020-10-22 | 2023-12-07 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| TWI883310B (zh) * | 2021-03-04 | 2025-05-11 | 南韓商愛迪恩斯股份有限公司 | 酞嗪酮化合物在製備用於治療人類奧拉帕尼抗藥性癌症之藥物的用途 |
| KR20220125183A (ko) | 2021-03-04 | 2022-09-14 | 아이디언스 주식회사 | Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도 |
| US20250312342A1 (en) * | 2021-06-02 | 2025-10-09 | Idience Co., Ltd. | Methods of treating disorders with phthalazinone derivatives |
| US20250120970A1 (en) * | 2022-01-25 | 2025-04-17 | Idience Co., Ltd. | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug |
| WO2024025389A1 (ko) * | 2022-07-29 | 2024-02-01 | 아이디언스 주식회사 | 프탈라지논 유도체의 중간체의 제조방법 |
| CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL223343B1 (pl) | 2000-10-30 | 2016-10-31 | Kudos Pharm Ltd | Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| WO2007138355A1 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| DK2120579T3 (da) * | 2006-12-28 | 2014-02-03 | Abbvie Inc | Inhibitorer af poly(ADP-ripose)polymerase |
| CN101030723A (zh) | 2007-04-04 | 2007-09-05 | 钟志华 | 电磁变相发动机 |
| ES2524787T3 (es) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8871765B2 (en) | 2010-07-27 | 2014-10-28 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372698A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| KR101528688B1 (ko) | 2010-12-02 | 2015-06-12 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 헤테로사이클릭 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
-
2014
- 2014-09-11 KR KR1020140120152A patent/KR101670126B1/ko active Active
- 2014-09-12 PL PL14843941.7T patent/PL3030557T3/pl unknown
- 2014-09-12 MX MX2016002998A patent/MX379467B/es unknown
- 2014-09-12 RS RS20230721A patent/RS64477B1/sr unknown
- 2014-09-12 RU RU2016108038A patent/RU2636585C2/ru active
- 2014-09-12 US US16/447,174 patent/USRE49338E1/en active Active
- 2014-09-12 WO PCT/KR2014/008523 patent/WO2015037939A1/en not_active Ceased
- 2014-09-12 PT PT148439417T patent/PT3030557T/pt unknown
- 2014-09-12 DK DK14843941.7T patent/DK3030557T3/da active
- 2014-09-12 AU AU2014319132A patent/AU2014319132C1/en active Active
- 2014-09-12 CN CN201480049174.5A patent/CN105793248B/zh active Active
- 2014-09-12 SI SI201432038T patent/SI3030557T1/sl unknown
- 2014-09-12 EP EP14843941.7A patent/EP3030557B1/en active Active
- 2014-09-12 BR BR112016004979-9A patent/BR112016004979B1/pt active IP Right Grant
- 2014-09-12 FI FIEP14843941.7T patent/FI3030557T3/fi active
- 2014-09-12 ES ES14843941T patent/ES2953834T3/es active Active
- 2014-09-12 MY MYPI2016700730A patent/MY195343A/en unknown
- 2014-09-12 SM SM20230268T patent/SMT202300268T1/it unknown
- 2014-09-12 LT LTEPPCT/KR2014/008523T patent/LT3030557T/lt unknown
- 2014-09-12 HU HUE14843941A patent/HUE062770T2/hu unknown
- 2014-09-12 JP JP2016542643A patent/JP6180643B2/ja active Active
- 2014-09-12 US US15/021,336 patent/US9682973B2/en active Active
- 2014-09-12 CA CA2923614A patent/CA2923614C/en active Active
- 2014-09-12 SG SG11201600549TA patent/SG11201600549TA/en unknown
- 2014-09-12 HR HRP20230998TT patent/HRP20230998T1/hr unknown
-
2016
- 2016-03-11 IL IL244548A patent/IL244548B/en active IP Right Grant
-
2017
- 2017-03-10 US US15/455,631 patent/US9844550B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9844550B2 (en) | Phtalazinone derivatives and manufacturing process thereof | |
| CN107474050B (zh) | 6，7-二氢吡唑并[1，5-a]吡嗪-4(5H)-酮化合物 | |
| US20210363139A1 (en) | Cxcr4 inhibitors and uses thereof | |
| CN115515947A (zh) | Shp2抑制剂及其组合物和应用 | |
| WO2020042995A1 (zh) | 一种高活性sting蛋白激动剂化合物 | |
| CN111386275B (zh) | 高活性sting蛋白激动剂 | |
| CN113582974A (zh) | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 | |
| CN107567454A (zh) | 用于治疗cns障碍的稠合二氢‑4h‑吡唑并[5,1‑c][1,4]噁嗪基化合物及其类似物 | |
| US20240238424A1 (en) | Heterobifunctional compounds and methods of treating disease | |
| WO2022184103A1 (zh) | 三并环化合物及其药物组合物和应用 | |
| CN112236428A (zh) | 抗增殖化合物及其用途 | |
| KR20260023023A (ko) | Wrn 억제제 | |
| WO2024188246A1 (zh) | 含氮大环类化合物及其制备方法和应用 | |
| WO2020169058A1 (zh) | Pd-l1拮抗剂化合物 | |
| HK1224280B (zh) | 酞嗪酮衍生物及其制备方法 | |
| WO2021139599A1 (zh) | RORγt抑制剂及其制备方法和用途 | |
| TWI810547B (zh) | Pd-l1拮抗劑化合物 | |
| WO2024264070A2 (en) | Akt inhibitors | |
| HK40047065A (en) | Antiproliferation compounds and uses thereof |